Home›Stock Screener›Rubicon Research

Rubicon Research Share Price Today | Stock Price & Rubicon Research Share Screener

RUBICON Pharmaceuticals & Biotechnology
Live Share Price NSE
₹1722.30
▲ 64.00 (3.86%)
2026-11-19 00:00:00
Live Share Price BSE
₹1726.00
▲ 64.20 (3.86%)
2026-11-19 00:00:00

As of November 19, 2026, the live Rubicon Research share price (NSE: RUBICON) is ₹1,722.30 on NSE and ₹1,726.00 on BSE, up 3.86% from the previous close, with shares trading between ₹1,650.80 and ₹1,745.10 in today's trading session, and a 52-week range of ₹615.20–₹1,860.60. Track Rubicon Research marketcap in USD to gauge the company's total market size. Use the Rubicon Research stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Rubicon Research opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹579 and net income of ₹90, with EBITDA of ₹146, an operating margin of 25.0% and a profit margin of 15.5%.

Rubicon Research Market Cap ₹27,873.92 Cr.
RUBICON P/E Ratio (TTM) 85.20
Rubicon Research P/B Ratio 19.54
EPS (TTM) ₹15.52
Dividend Yield 0.09%
Debt to Equity 0.40
RUBICON 52 Week High ₹1860.60
Rubicon Research 52 Week Low ₹615.20
Operating Margin 25.00%
Profit Margin 15.54%
RUBICON Revenue (TTM) ₹579.00
EBITDA ₹146.00
Net Income ₹90.00
Total Assets ₹2,327.00
Total Equity ₹1,289.00

Rubicon Research Share Price Chart

Track the current stock price of Rubicon Research with an interactive chart. Analyse RUBICON share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Rubicon Research stock quote in one place.

The quote of ₹1,722.30 sits between the 52-week low of ₹615.20 and the 52-week high of ₹1,860.60, and the latest session moved 3.86% from the previous close.

Rubicon Research Company Profile - Fundamental Screener

Screen Rubicon Research company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for RUBICON shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE506V01022.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE506V01022

Rubicon Research Balance Sheet Screener

Screen RUBICON balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹2,327, up from ₹1,451 in 2025.

Latest statistics put total assets at ₹2,327 and shareholder funds at ₹1,289, with a leverage ratio of 0.40.

Item 2026 2025 2024 2023 2022 2021 2020

Assets

Total Assets 2,327 1,451 1,110 750 560 538 430
Current Assets 0 0 0 0 0 0 0
Fixed Assets 532 327 307 199 193 188 157

Liabilities

Total Liabilities 0 0 0 0 0 0 0
Current Liabilities 202 124 152 102 71 53 12
Non-Current Liabilities 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 1,289 541 385 286 305 374 341
Share Capital 17 15 15 5 5 5 5
Reserves & Surplus 1,272 526 370 281 300 369 335

Rubicon Research Income Statement Screener - Profit & Revenue Analysis

Screen Rubicon Research income statement and profit fundamentals. Analyze RUBICON quarterly results. Rubicon Research reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹579 and net profit was ₹90, equal to earnings per unit of ₹5.47, at an operating margin of 25%.

In that period expenses were ₹432, interest cost ₹11 and tax ₹27. The next period listed, 2026-Jun, shows revenue of ₹540 and net profit of ₹85.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun

Revenue and Expenses

Revenue 579 540 517 479 413 353 358 314 299 317
Expenses 432 405 395 367 318 273 286 244 234 257

Operating Costs and Margins

EBITDA 146 135 121 112 95 80 73 70 64 61
Operating Profit % 25.00% 24.00% 23.00% 23.00% 23.00% 22.00% 20.00% 22.00% 21.00% 19.00%
Depreciation 18 15 12 12 12 10 10 9 8 9
Interest 11 9 10 10 11 11 12 8 7 10

Profit and Earnings

Profit Before Tax 117 110 99 91 72 60 51 53 49 41
Tax 27 26 22 18 18 16 15 15 15 16
Net Profit 90 85 77 73 54 43 36 38 35 26
EPS 5.47 5.13 4.68 4.46 3.49 2.81 2.37 2.50 2.27 1.66

Rubicon Research Cash Flow Screener - Liquidity Fundamentals

Screen RUBICON cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹205, and net cash flow was an inflow of ₹81.

Over the same period, investing activities used ₹407 and financing activities provided ₹283.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March

Cash from Operations and Investing

Operating Activities 205 159 21 -75 -63 62 6
Investing Activities -407 -65 -68 -32 -46 -46 -84

Financing and Net Cash

Financing Activities 283 -40 44 123 63 52 80
Net Cash Flow 81 54 -4 16 -46 67 1

Rubicon Research Shareholding Pattern Screener

See Rubicon Research shareholding pattern with promoter, FII, and DII holdings. Check Rubicon Research promoter holding and ownership changes for RUBICON on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 59.86%, foreign institutions 7.54%, domestic institutions 10.02% and the public 2.82%, spread across 33,738 shareholders.

The shareholder count was 33,738 in 2026-Mar, compared with 43,254 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Sept 2025-Oct 2025-Dec 2024-Jul

Promoter Holding

Promoter Holding 59.86% 59.76% 51.25% 59.99% 59.99% 59.99% 84.15%

Institutional Investors

FII Holding 7.54% 7.52% 9.01% 9.37% 9.37% 7.99% 0.00%
DII Holding 10.02% 9.43% 15.72% 10.54% 10.54% 9.45% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 2.82% 3.46% 3.89% 18.28% 18.28% 2.71% 0.00%
Other Holding 19.76% 19.84% 20.13% 1.82% 1.82% 19.86% 15.85%
Shareholder Count 33,738 43,254 38,018 105,311 105,311 31,914 15

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Rubicon Research. Rubicon Research dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹1.50 per unit for 2026-March, a yield of 0.09%, compared with ₹0.02 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹1.50, ₹0.02 and ₹0.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹1.50 0.09%
2025-March ₹0.02 0.00%
2024-March ₹0.00 0.00%
2023-March ₹0.00 0.00%
2022-March ₹0.00 0.00%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Rubicon Research Stock Index Membership - Nifty & Sensex

See which indices include Rubicon Research stock. Check RUBICON index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Rubicon Research is not part of any tracked indices.
Only major market indices are tracked in our system.

Rubicon Research Market Events Screener - Corporate Actions

Get Rubicon Research corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Rubicon Research stock events that may affect RUBICON share price, along with derivatives, futures and options activity and sector gainers.

7 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 5, 2026, with a record date of November 5, 2026.

It is followed by Annual General Meeting dated August 26, 2026 and Quarterly Result Announcement dated August 14, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-05 2026-11-05 Quarterly Result Announcement NA 14.84%
2026-08-26 2026-08-26 Annual General Meeting NA 18.65%
2026-08-14 2026-08-14 Quarterly Result Announcement NA 5.72%
2026-08-07 2026-08-07 Dividend ₹ 1.50 /share 58.39%
2026-05-29 2026-05-29 Quarterly Result Announcement NA -0.12%
2026-02-03 2026-02-03 Quarterly Result Announcement NA 5.98%
2025-11-13 2025-11-13 Quarterly Result Announcement NA -1.76%

Rubicon Research Competitors Screener - Peer Stocks Comparison

Screen RUBICON competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,676 40.80 61,674 12.69% 11,565 60.46
Divis Laboratories 295,997 87.70 11,067 13.95% 2,568 68.76
Torrent Pharmaceuticals 177,586 85.00 13,886 20.34% 2,138 47.23
Laurus Labs 126,325 89.90 6,868 22.01% 890 57.04
Zydus Life Science 120,119 27.60 27,658 17.64% 5,026 55.91
Dr Reddys Laboratories 115,854 41.80 35,059 3.90% 4,158 71.26
Cipla 112,131 39.50 29,045 2.24% 3,870 53.06
Mankind Pharma 107,805 47.90 14,636 14.85% 1,938 61.37
Aurobindo Pharma 103,229 25.80 34,145 5.56% 3,503 60.39
Lupin 89,172 17.30 29,039 26.75% 5,356 39.39

Rubicon Research Company Announcements - News & Reports Screener

Screen RUBICON latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 17, 2026.

The next most recent announcements are dated November 15, 2026 and November 6, 2026.

Date Update Actions
2026-11-17 Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) W.R.T Update On The Scheme Of Merger Between Rubicon Research Ltd And KIA Health Tech Pvt Ltd. -
2026-11-15 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-11-06 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-05 Audio Recording Of Earnings Conference Call For Thequarter Ended 30Th September 2026. -
2026-11-05 Announcement under Regulation 30 (LODR)-Monitoring Agency Report -
2026-11-05 Announcement under Regulation 30 (LODR)-Monitoring Agency Report -
2026-11-05 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-11-05 Board Meeting Outcome for Outcome Of The Board Meeting Held On November 5 2026 -
2026-11-05 Grant Of Stock Options Under Rubicon Research Limited Stock Option Plan 2026 -
2026-10-30 Outcome Of USFDA Inspection Of Rubicon Research Ltd Manufacturing Facility In Ambernath India. -
2026-10-28 Intimation Regarding Q2 Earnings Conference Call. -
2026-10-27 Board Meeting Intimation for Q 2 Ended September 2026. -
2026-10-09 Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -US FDA Inspection Of The Companys Manufacturing Facility In Satara Maharashtra India. -
2026-10-09 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-08 Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS -
2026-09-28 Closure of Trading Window -
2026-08-29 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-08-27 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-08-26 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-08-26 Shareholder Meeting / Postal Ballot-Outcome of AGM -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹1,722.30, within a 52-week range of ₹615.20 to ₹1,860.60. The P/E ratio is 85.20 and the P/B ratio is 19.54, with earnings per unit of ₹15.52. Market capitalisation stands at ₹27,873.92 Cr and the dividend yield is 0.09%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 7 balance sheet periods, 10 income statement periods, 7 cash flow years and 7 shareholding periods. Information is provided for research and is not investment advice.